| Literature DB >> 11922200 |
Lucia Mayordomo1, Jose Luis Marenco, Jesus Gomez-Mateos, Eduardo Rejon.
Abstract
No difference in the number of serious adverse events was reported in previous clinical trials in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) patients treated with TNF-alpha blockade, but a patient died because of disseminated tuberculosis. A tuberculosis reactivation in a patient with IBD and anti-TNF-alpha treatment has been recently reported. Very recently 70 cases of tuberculosis were reported from the FDA Adverse Event Reporting System. We report a case of pulmonary miliary tuberculosis in a RA patient treated with TNF-alpha blockade. The important role of TNF-alpha in defence against tuberculosis and possible mechanisms of anti-TNF-alpha agents impairing tuberculosis immune response are discussed.Entities:
Mesh：
Substances：
Year: 2002 PMID： 11922200 DOI： 10.1080/030097402317255372
Source DB: PubMed Journal: Scand J Rheumatol ISSN： 0300-9742 Impact factor: 3.641